OCS vs. ABUS, KALV, APLT, FULC, ANL, CMPS, ANAB, IGMS, SLRN, and STTK
Should you be buying Oculis stock or one of its competitors? The main competitors of Oculis include Arbutus Biopharma (ABUS), KalVista Pharmaceuticals (KALV), Applied Therapeutics (APLT), Fulcrum Therapeutics (FULC), Adlai Nortye (ANL), COMPASS Pathways (CMPS), AnaptysBio (ANAB), IGM Biosciences (IGMS), Acelyrin (SLRN), and Shattuck Labs (STTK). These companies are all part of the "pharmaceutical preparations" industry.
Arbutus Biopharma (NASDAQ:ABUS) and Oculis (NASDAQ:OCS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability, community ranking and analyst recommendations.
Arbutus Biopharma received 407 more outperform votes than Oculis when rated by MarketBeat users. However, 85.00% of users gave Oculis an outperform vote while only 70.78% of users gave Arbutus Biopharma an outperform vote.
43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. 5.4% of Arbutus Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Arbutus Biopharma has higher revenue and earnings than Oculis.
Arbutus Biopharma currently has a consensus price target of $4.33, suggesting a potential upside of 58.73%. Oculis has a consensus price target of $29.14, suggesting a potential upside of 142.45%. Given Arbutus Biopharma's higher probable upside, analysts plainly believe Oculis is more favorable than Arbutus Biopharma.
In the previous week, Oculis had 12 more articles in the media than Arbutus Biopharma. MarketBeat recorded 14 mentions for Oculis and 2 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 0.34 beat Oculis' score of 0.00 indicating that Oculis is being referred to more favorably in the news media.
Oculis has a net margin of 0.00% compared to Oculis' net margin of -401.57%. Arbutus Biopharma's return on equity of 0.00% beat Oculis' return on equity.
Summary
Oculis beats Arbutus Biopharma on 9 of the 14 factors compared between the two stocks.
Get Oculis News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
